BlissBio Goes Solo On HER2-Targeting ADC After Eisai Exit

New Results Ahead Of Planned IPO

 
• By Dexter Jie Yan
  
Bliss Biopharmaceutical is now on a solo quest to develop BB-1701, its HER2-targeting ADC. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D